Abstract #4239

Minimizing the confounding effect of gadolinium contrast on subsequent ferumoxytol MRI in the brain

Csanad Gyorgy Varallyay¹, Andrea Horvath², Gerda Toth², Laszlo Szidonya², Emily Youngers², and Edward Neuwelt³

¹Dept. of Radiology, Oregon Health and Science University, Portland, OR, United States, ²Oregon Health and Science University, Portland, OR, United States, ³Dept. of Neurology, Oregon Health and Science University, Portland, OR, United States

Ferumoxytol as an MRI contrast agent has the advantage of long intravascular phase and strong transverse relaxivity, allowing high resolution depiction of abnormal vasculature and steady state blood volume (SS-CBV) mapping. In clinical studies it would be beneficial to use ferumoxytol as an immediate extension of standard of care gadolinium enhanced MRI, instead of imaging on two separate days. This study concludes that the 3D T2* weighted acquisition has substantial T1 weighting, while the 2D acquisition does not, therefore the latter one is preferable for ferumoxytol vascular imaging if gadolinium is on board.

This abstract and the presentation materials are available to members only; a login is required.

Join Here